Hong Xu1,2, Alessandro Gasparini2,3, Junichi Ishigami4, Khaled Mzayen5, Guobin Su5,6, Peter Barany2, Johan Ärnlöv7,8, Bengt Lindholm2, Carl Gustaf Elinder2, Kunihiro Matsushita4, Juan Jesús Carrero9,2. 1. Departments of Medical Epidemiology and Biostatistics and. 2. Division of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. 3. Department of Health Sciences, University of Leicester, Leicester, United Kingdom. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 5. Public Health Sciences and. 6. Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou City, Guangdong Province, China. 7. School of Health and Social Studies, Dalarna University, Falun, Sweden; and. 8. Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden. 9. Departments of Medical Epidemiology and Biostatistics and juan.jesus.carrero@ki.se.
Abstract
BACKGROUND AND OBJECTIVES: Community-acquired infections are common, contributing to adverse outcomes and increased health care costs. We hypothesized that, with lower eGFR, the incidence of community-acquired infections increases, whereas the pattern of site-specific infections varies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 1,139,470 health care users (mean age =52±18 years old, 53% women) from the Stockholm CREAtinine Measurements Project, we quantified the associations of eGFR with the risk of infections, overall and major types, over 12 months. RESULTS: A total of 106,807 counts of infections were recorded throughout 1,128,313 person-years. The incidence rate of all infections increased with lower eGFR from 74/1000 person-years for individuals with eGFR=90-104 ml/min per 1.73 m2 to 419/1000 person-years for individuals with eGFR<30 ml/min per 1.73 m2. Compared with eGFR of 90-104 ml/min per 1.73 m2, the adjusted incidence rate ratios of community-acquired infections were 1.08 (95% confidence interval, 1.01 to 1.14) for eGFR of 30-59 ml/min per 1.73 m2 and 1.53 (95% confidence interval, 1.39 to 1.69) for eGFR<30 ml/min per 1.73 m2. The relative proportions of lower respiratory tract infection, urinary tract infection, and sepsis became increasingly higher along with lower eGFR strata (e.g., low respiratory tract infection accounting for 25% versus 15% of community-acquired infections in eGFR<30 versus 90-104 ml/min per 1.73 m2, respectively). Differences in incidence associated with eGFR were in general consistent for most infection types, except for nervous system and upper respiratory tract infections, for which no association was observed. CONCLUSIONS: This region-representative health care study finds an excess community-acquired infections incidence in individuals with mild to severe CKD. Lower respiratory tract infection, urinary tract infection, and sepsis are major infections in CKD.
BACKGROUND AND OBJECTIVES: Community-acquired infections are common, contributing to adverse outcomes and increased health care costs. We hypothesized that, with lower eGFR, the incidence of community-acquired infections increases, whereas the pattern of site-specific infections varies. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 1,139,470 health care users (mean age =52±18 years old, 53% women) from the Stockholm CREAtinine Measurements Project, we quantified the associations of eGFR with the risk of infections, overall and major types, over 12 months. RESULTS: A total of 106,807 counts of infections were recorded throughout 1,128,313 person-years. The incidence rate of all infections increased with lower eGFR from 74/1000 person-years for individuals with eGFR=90-104 ml/min per 1.73 m2 to 419/1000 person-years for individuals with eGFR<30 ml/min per 1.73 m2. Compared with eGFR of 90-104 ml/min per 1.73 m2, the adjusted incidence rate ratios of community-acquired infections were 1.08 (95% confidence interval, 1.01 to 1.14) for eGFR of 30-59 ml/min per 1.73 m2 and 1.53 (95% confidence interval, 1.39 to 1.69) for eGFR<30 ml/min per 1.73 m2. The relative proportions of lower respiratory tract infection, urinary tract infection, and sepsis became increasingly higher along with lower eGFR strata (e.g., low respiratory tract infection accounting for 25% versus 15% of community-acquired infections in eGFR<30 versus 90-104 ml/min per 1.73 m2, respectively). Differences in incidence associated with eGFR were in general consistent for most infection types, except for nervous system and upper respiratory tract infections, for which no association was observed. CONCLUSIONS: This region-representative health care study finds an excess community-acquired infections incidence in individuals with mild to severe CKD. Lower respiratory tract infection, urinary tract infection, and sepsis are major infections in CKD.
Authors: Linda F Fried; Ronit Katz; Mark J Sarnak; Michael G Shlipak; Paulo H M Chaves; Nancy Swords Jenny; Catherine Stehman-Breen; Dan Gillen; Anthony J Bleyer; Calvin Hirsch; David Siscovick; Anne B Newman Journal: J Am Soc Nephrol Date: 2005-10-26 Impact factor: 10.121
Authors: Matthew T James; Hude Quan; Marcello Tonelli; Braden J Manns; Peter Faris; Kevin B Laupland; Brenda R Hemmelgarn Journal: Am J Kidney Dis Date: 2009-05-17 Impact factor: 8.860
Authors: Matthew T James; Kevin B Laupland; Marcello Tonelli; Braden J Manns; Bruce F Culleton; Brenda R Hemmelgarn Journal: Arch Intern Med Date: 2008-11-24
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Björn Runesson; Alessandro Gasparini; Abdul Rashid Qureshi; Olof Norin; Marie Evans; Peter Barany; Björn Wettermark; Carl Gustaf Elinder; Juan Jesús Carrero Journal: Clin Kidney J Date: 2015-11-14
Authors: Junichi Ishigami; Jonathan T Taliercio; Harold I Feldman; Anand Srivastava; Raymond R Townsend; Debbie L Cohen; Edward J Horwitz; Panduranga Rao; Jeanne Charleston; Jeffrey C Fink; Ana C Ricardo; James Sondheimer; Teresa K Chen; Myles Wolf; Tamara Isakova; Lawrence J Appel; Kunihiro Matsushita Journal: J Am Soc Nephrol Date: 2020-06-23 Impact factor: 10.121
Authors: Junichi Ishigami; Ron C Hoogeveen; Christie M Ballantyne; Aaron R Folsom; Josef Coresh; Elizabeth Selvin; Kunihiro Matsushita Journal: Am J Epidemiol Date: 2019-12-31 Impact factor: 4.897
Authors: Junichi Ishigami; Jonathan Taliercio; Harold I Feldman; Anand Srivastava; Raymond Townsend; Debbie L Cohen; Edward Horwitz; Panduranga Rao; Jeanne Charleston; Jeffrey C Fink; Ana C Ricardo; James Sondheimer; Teresa K Chen; Myles Wolf; Tamara Isakova; Lawrence J Appel; Kunihiro Matsushita Journal: Am J Epidemiol Date: 2020-05-05 Impact factor: 4.897
Authors: Hong Xu; Sara Garcia-Ptacek; Marco Trevisan; Marie Evans; Bengt Lindholm; Maria Eriksdotter; Juan Jesus Carrero Pharm Journal: Neurology Date: 2021-05-05 Impact factor: 9.910